StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Investment analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Wednesday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Price Performance

Shares of NSPR stock opened at $3.01 on Wednesday. InspireMD has a one year low of $1.81 and a one year high of $3.42. The stock has a fifty day moving average price of $2.61 and a 200 day moving average price of $2.65. The stock has a market cap of $78.50 million, a P/E ratio of -3.92 and a beta of 0.98.

InspireMD (NYSE:NSPR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. During the same quarter in the previous year, the firm earned ($0.15) EPS. Equities research analysts anticipate that InspireMD will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NSPR. Affiance Financial LLC acquired a new stake in shares of InspireMD during the 3rd quarter worth approximately $492,000. Parkman Healthcare Partners LLC acquired a new stake in InspireMD during the 3rd quarter worth $279,000. Finally, Rosalind Advisors Inc. raised its position in shares of InspireMD by 266.4% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after acquiring an additional 1,827,579 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.